Artelo Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Artelo Biosciences Inc ARTL.OQ reported a quarterly adjusted loss of $5.61​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-4.50. The lone analyst forecast for the quarter was for a loss of $4.19 per share.

• Reported revenue was zero​; analysts expected zero.

• Artelo Biosciences Inc's reported EPS for the quarter was a loss of $5.61​.

• The company reported a quarterly loss of $3.22 million.

• Artelo Biosciences Inc shares had fallen by 26.8% this quarter and gained 52.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 437.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Artelo Biosciences Inc is $24.00, about 59.5% above its last closing price of $9.72

This summary was machine generated from LSEG data August 13 at 12:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)